SPOTLIGHT -
Des Plaines, IL-First-quarter 2004 sales of Addition Technology Inc.'s micro-thin prescription inserts (Intacs) increased 57% over the same period a year ago and 93% over the previous quarter, according to the company.
Aurion Biotech doses first Canadian patient in Phase 1/2 ABA-1, CLARA clinical trial of AURN001
EyePod: Modifier Gene Therapy: What is it?
Navigating ocular effects of cancer therapy: Insights from breast cancer and head-neck cancers
EyePod: Integrating cutting-edge pipeline devices for enhanced cataract surgery
ABVC BioPharma reaches global licensing deal for ophthalmology pipeline
Plastic surgery: When specialties overlap